Advice

In the absence of a submission from the holder of the marketing authorisation:

fondaparinux sodium 1.5mg/0.3mL solution for injection, pre-filled syringe (Arixtra ®): is not recommended for use in NHSScotland.                                   

Indication under review: treatment of acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Download detailed advice69KB (PDF)

Download

Medicine details

Medicine name:
fondaparinux sodium (Arixtra)
SMC ID:
668/10
Indication:
Treatment of acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis
Pharmaceutical company
GlaxoSmithKline UK Ltd
BNF chapter
Cardiovascular system
Submission type
Non submission
Status
Not recommended
Date advice published
13 December 2010